

January 2025



Dear Valued Distributors,

The purpose of this letter is to provide an **update on end-user BD Hypodermic allocation adjustments** following our December communication.

In December, BD implemented hypodermic allocation adjustments to support inventory supply health for all as we manage demand increase resulting from recent IV fluid shortage and inventory reduction on Private Label syringes made in China.

We are pleased to share that **supply health has improved over the last month. As a result, additional codes have been removed from manual allocation or had benchmarks revised to a higher threshold** as supply health improves.

See table below with revisions in green:

SKU	Description	Dec. 2024 Allocation	January 2025 Allocation
302830	20mL Luer Lok Syringe	100%	100%
302832	30mL Luer Lok Syringe	120%	140%
302995	10mL Luer Lok Syringe	105%	110%
305062	5mL Blunt Fill w/ NDL 18GX 1.5	100%	100%
305064	10mL Blunt Fill w/ NDL 18GX 1.5	120%	120%
305789	1mL Luer Lok Syringe w/ NDL 27GX1/2	150%	Removed from manual allocation
309642	10mL Luer Lok Syringe w/NDL 21GX1	100%	Removed from manual allocation
309646	5mL Luer Lok Syringe	75%	75%
309647	5mL Luer Slip Syringe	100%	120%
309657	3mL Luer Lok Syringe	100%	100%

BD also recently announced additional investments in its U.S. manufacturing network to expand capacity for critical medical devices, including needles and syringes. This expansion includes new 5mL and 10mL bulk non-sterile and BD SafetyGlide™ needle and syringe lines at BD facilities in Nebraska and Connecticut that will boost BD's output of conventional and safety-engineered devices to support U.S. health care delivery. Read the press release regarding BD manufacturing line investment [here](#).

In addition, BD continues to partner with market leaders for custom/procedural kits to incorporate BD syringes, decreasing the need to pull sterile syringes separately. We look forward to the launch of our new 5mL and 10mL bulk non-sterile manufacturing lines, which will further support incremental manufacturing of sterile supply.

We will continue to communicate updates regarding these benchmarks and supply health improvements.

For any questions on allocation benchmarks, please align with your BD and distribution sales representatives.

Thank you for your continued support.



Chelsea Montufar

Marketing Manager, Core Hypodermics

US Region

Click [here](#) to learn more about our BD Hypodermic Needle and Syringe Portfolio